SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Agouron Pharmaceuticals (AGPH)
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: John Metcalf who wrote (852)6/24/1997 12:52:00 PM
From: Peter Silsbee   of 6136
 
Roche released this last week:

Largest ever HIV drug study shows Invirase dramatically reduces the onset of AIDS

roche.com

Of course, due to AGPH's unusual deal with Roche, European sales of Invirase are good for AGPH as well.

Report includes this quote: "Importantly for patients, we know from extensive clinical experience, that saquinavir is the best tolerated protease inhibitor." This is not what I seem to remember, can anyone confirm or provide contradictory evidence?

PLS
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News